Hopewell Therapeutics has filed a notice of an exempt offering of securities to raise $10,000,001.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Hopewell Therapeutics is raising $10,000,001.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Louis Brenner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Hopewell Therapeutics
Hopewell Therapeutics Inc. is developing novel synthetic biodegradable lipid based nanoparticles for nucleic acid delivery for gene therapy and gene editing. The technology is licensed from Tufts University. We have identified LNPs that can deliver cargos in organ and cell specific manner. Our mission is to provide cutting-edge technology and services in the field of immunotherapy, gene therapy and gene editing.
To learn more about Hopewell Therapeutics, visit http://www.hopewell-tx.com/
Contact:
Louis Brenner, President and Chief Executive Officer
617-921-7082
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.